Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E(2022) Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study Acta Oncol, 61(8), 955-962 DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM(2022) Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192] J Control Release, 349, 1(in press) DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R(2022) Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer Front Oncol, 12, 873516 DOI 10.3389/fonc.2022.873516, PubMed 35692804